A few months ago, we were talking about the refusal of Stallergenes’ minority shareholders to merge with Greer laboratories, another competitor within the field of allergy treatment. Finally, Stallergenes shareholders accepted, and both companies are going to create the world leader in allergy immunotherapy.
After the sale of Serono to Merck back in 2007, the magnate Ernesto Bertarelli started its own investment companies and is still at the front of the scene with its last billion-fund Gurnet Point Capital run by Chris Viehbacher. Today, it’s the turn of Ares Life Sciences, the first of Bertarelli’s investment companies to make the cover page. Through Ares Allergy Holdings PLC, the investment company holds 77% of the French company Stallergenes and 100% of the American Company Greer Laboratories. In a nutshell, Ares Allergy Holdings just bagged two leaders in the Allergy field.
A few months ago, Ares tried to merge Stallergenes with Greer Laboratories. And as we explained, with this proposition Ares found a strong opposition amongst minority shareholders that saw the investment group as the only beneficiary of the fusion.